Logo

LYEL

Lyell Immunopharma, Inc.

LYEL

Lyell Immunopharma, Inc. • NASDAQ
$24.00 ▼ -1.68% (-0.41)
Market Cap $509.23 M
52w High $25.20
52w Low $7.65
Dividend Yield 0%
P/E -1.05
Volume 36.97K
Outstanding Shares 21.22M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $15K ▲ $37.268M ▼ $-38.846M ▲ -258.973K% ▲ $-2.13 ▲ $-36.28M ▲
Q2-2025 $8K ▲ $47.148M ▼ $-42.684M ▲ -533.55K% ▲ $-2.89 ▼ $-42.562M ▲
Q1-2025 $7K ▼ $57.374M ▼ $-52.195M ▲ -745.643K% ▲ $-0.18 ▲ $-53.926M ▲
Q4-2024 $11K ▼ $201.158M ▲ $-191.935M ▼ -1.745M% ▼ $-0.72 ▼ $-57.64M ▼
Q3-2024 $34K $50.539M $-44.583M -131.126K% $-0.17 $-45.825M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $319.624M ▲ $407.965M ▲ $78.844M ▼ $329.121M ▲
Q2-2025 $276.79M ▼ $385.453M ▼ $86.53M ▼ $298.923M ▼
Q1-2025 $301.177M ▼ $429.798M ▼ $93.277M ▼ $336.521M ▼
Q4-2024 $370.527M ▼ $490.859M ▼ $108.035M ▲ $382.824M ▼
Q3-2024 $440.547M $619.215M $88.518M $530.697M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-38.846M ▲ $-28.577M ▲ $3.349M ▼ $50M ▲ $24.771M ▲ $-28.639M ▲
Q2-2025 $-42.684M ▲ $-34.458M ▲ $12.647M ▼ $183K ▲ $-21.628M ▼ $-34.626M ▲
Q1-2025 $-52.195M ▲ $-54.738M ▼ $69.466M ▲ $1K ▼ $14.729M ▲ $-54.984M ▼
Q4-2024 $-191.935M ▼ $-47.242M ▼ $53.505M ▲ $437K ▲ $5.298M ▲ $-47.286M ▼
Q3-2024 $-44.583M $-35.042M $1.918M $0 $-33.124M $-35.101M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025
Reportable segment
Reportable segment
 $0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Lyell is still essentially a pre‑revenue biotech story. Reported sales are negligible and do not yet support the cost base. Operating losses have been sizable and have generally grown over time, reflecting heavy investment in research, clinical trials, and infrastructure. Net results are consistently negative, with per‑share losses widening most recently. This pattern is typical for a clinical‑stage biotech focused on platform and pipeline build‑out rather than near‑term profitability.

Balance Sheet

Balance Sheet The company started with a strong post‑IPO balance sheet and still carries more assets than liabilities, but the cushion has been shrinking as losses accumulate. Cash reserves have come down from earlier peaks, while total assets and shareholders’ equity have trended lower, showing that capital is being consumed faster than it is being replenished. On the positive side, debt levels are modest, so the balance sheet is not heavily leveraged; the main risk is eventual capital needs, not current indebtedness.

Cash Flow

Cash Flow Lyell consistently spends more cash than it brings in from operations. Operating cash outflows have been steady and sizeable, driven by R&D and overhead with no commercial inflows yet. Free cash flow is clearly negative, though capital spending has eased from earlier build‑out years, meaning the burn now is mostly operating rather than driven by big facility investments. Over time, this pattern implies reliance on external financing or partnerships unless the company can generate meaningful collaboration or product revenue.

Competitive Edge

Competitive Edge Competitively, Lyell is aiming at a difficult but high‑value niche: cell therapies for solid tumors and improved CAR T approaches. Its edge comes from differentiated T‑cell reprogramming platforms, in‑house manufacturing capacity, and notable collaborations with larger industry players. Early clinical signals from lead programs, especially ronde‑cel, appear encouraging versus current standards in certain lymphomas. However, the company operates in a crowded and rapidly evolving cell therapy field dominated by large pharma and well‑funded biotechs, with high scientific, regulatory, and commercial execution risk. Its portfolio is still concentrated in a few key programs, so setbacks in those would weigh heavily on its competitive standing.

Innovation and R&D

Innovation and R&D Innovation is the main strength of Lyell. It has multiple proprietary platforms (Gen‑R, Epi‑R, Stim‑R) designed to improve T‑cell persistence and potency, particularly in hostile solid tumor environments, and these technologies can be combined to create more advanced therapies. The pipeline spans next‑generation CAR T, TIL products, and novel solid tumor targets, supported by preclinical and early clinical data that suggest meaningful biological activity. The company has shown discipline by discontinuing weaker programs to prioritize assets with better prospects, but those same cuts underscore how uncertain and iterative this kind of science is. Overall, Lyell is R&D‑heavy, science‑driven, and likely to remain so for years, with long timelines before any potential commercial payoff.

Summary

Lyell is a classic high‑risk, high‑uncertainty clinical‑stage biotech: strong scientific ambition and platform depth, but with no material revenue and ongoing financial losses. Its balance sheet still provides some buffer, with low debt but a steadily shrinking capital base as cash is spent on R&D and operations. Cash burn is consistent and significant, implying eventual dependence on additional funding or broader partnerships. Competitively, Lyell’s focus on solving T‑cell exhaustion and improving durability in solid tumors, backed by proprietary technologies and manufacturing, gives it a differentiated story in a very competitive space. The key uncertainties center on clinical outcomes, regulatory pathways, timing of any potential approvals, and the company’s ability to manage its cash runway while advancing multiple complex programs.

NEWS

November 12, 2025 · 4:05 PM UTC

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025

Read more

November 10, 2025 · 7:30 AM UTC

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

Read more

November 3, 2025 · 9:00 AM UTC

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Read more

September 3, 2025 · 8:00 AM UTC

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

Read more

September 2, 2025 · 4:05 PM UTC

Lyell Immunopharma Announces Participation in September Investor Conferences

Read more